AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
triamterene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2728 | 396-01-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.10 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.03 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 10 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 13.15 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 51 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 13 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 63 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.42 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 4.30 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 1.201 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 2.360 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 15.849 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 2.559 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 46.320 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 56.580 | % | High | 1 |
| herg | hERG pIC50 | 4.522 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.560 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.133 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 39.890 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,CAMK2B,CAMK2D,CDK1,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,ITK,JAK1,JAK3,MAP3K1,MAP3K10,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK7,MAPK9,MARK4,MET,MTOR,NTRK2,PDK2,PIK3CA,PIK3CD,PIK3CG,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 46 | |||
| kinase-selectivity-class | AXL,MAP2K3,MAP3K21,MAPK7,PIK3CD,PIK3CG | 6 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 3.428 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 4.699 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 46.040 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 5.623 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 56.520 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 2.339 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 88.680 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 51.320 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 106.660 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 10, 1964 | FDA | CONCORDIA PHARMS INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pneumonia aspiration | 65.98 | 14.46 | 46 | 9805 | 40894 | 90577702 |
| Gastrooesophageal reflux disease | 49.95 | 14.46 | 75 | 9776 | 166262 | 90452334 |
| Coma | 43.04 | 14.46 | 46 | 9805 | 72586 | 90546010 |
| Crystal nephropathy | 38.37 | 14.46 | 11 | 9840 | 1140 | 90617456 |
| Myocardial infarction | 37.98 | 14.46 | 52 | 9799 | 105920 | 90512676 |
| Focal segmental glomerulosclerosis | 37.27 | 14.46 | 12 | 9839 | 1839 | 90616757 |
| Blood potassium decreased | 37.05 | 14.46 | 35 | 9816 | 47692 | 90570904 |
| Hyponatraemia | 34.21 | 14.46 | 56 | 9795 | 133482 | 90485114 |
| Underdose | 31.62 | 14.46 | 34 | 9817 | 53983 | 90564613 |
| Somnolence | 29.36 | 14.46 | 68 | 9783 | 209016 | 90409580 |
| Diabetic neuropathy | 26.71 | 14.46 | 12 | 9839 | 4562 | 90614034 |
| Feeling abnormal | 26.40 | 14.46 | 57 | 9794 | 167178 | 90451418 |
| Treatment failure | 22.89 | 14.46 | 3 | 9848 | 303925 | 90314671 |
| Oedema peripheral | 21.27 | 14.46 | 69 | 9782 | 257846 | 90360750 |
| Pulmonary embolism | 21.11 | 14.46 | 45 | 9806 | 130775 | 90487821 |
| Glossodynia | 20.30 | 14.46 | 5 | 9846 | 321774 | 90296822 |
| Infusion related reaction | 20.26 | 14.46 | 10 | 9841 | 416770 | 90201826 |
| Drug intolerance | 19.92 | 14.46 | 12 | 9839 | 447579 | 90171017 |
| Cardiac failure congestive | 19.57 | 14.46 | 37 | 9814 | 98657 | 90519939 |
| Lung neoplasm | 19.55 | 14.46 | 11 | 9840 | 6724 | 90611872 |
| Ileus paralytic | 19.51 | 14.46 | 10 | 9841 | 5075 | 90613521 |
| Transient acantholytic dermatosis | 19.45 | 14.46 | 4 | 9847 | 101 | 90618495 |
| Coronary artery disease | 19.39 | 14.46 | 21 | 9830 | 33602 | 90584994 |
| Blood pressure increased | 19.27 | 14.46 | 56 | 9795 | 197161 | 90421435 |
| Product use issue | 19.18 | 14.46 | 6 | 9845 | 329913 | 90288683 |
| Tubulointerstitial nephritis | 18.55 | 14.46 | 18 | 9833 | 25325 | 90593271 |
| Wound | 18.55 | 14.46 | 5 | 9846 | 302975 | 90315621 |
| Deep vein thrombosis | 17.74 | 14.46 | 34 | 9817 | 91586 | 90527010 |
| Photosensitivity reaction | 17.66 | 14.46 | 15 | 9836 | 17792 | 90600804 |
| Vitamin B6 deficiency | 16.69 | 14.46 | 4 | 9847 | 206 | 90618390 |
| Fear | 16.48 | 14.46 | 14 | 9837 | 16608 | 90601988 |
| Dry skin | 16.22 | 14.46 | 32 | 9819 | 88041 | 90530555 |
| Cerebrovascular accident | 16.05 | 14.46 | 39 | 9812 | 123494 | 90495102 |
| Dehydration | 16.00 | 14.46 | 52 | 9799 | 194395 | 90424201 |
| Off label use | 15.84 | 14.46 | 64 | 9787 | 1102188 | 89516408 |
| Renal failure | 15.59 | 14.46 | 40 | 9811 | 130967 | 90487629 |
| Myalgia | 15.47 | 14.46 | 48 | 9803 | 175077 | 90443519 |
| Hypersomnia | 15.22 | 14.46 | 15 | 9836 | 21516 | 90597080 |
| Completed suicide | 14.95 | 14.46 | 42 | 9809 | 145016 | 90473580 |
| Hypokalaemia | 14.54 | 14.46 | 39 | 9812 | 131077 | 90487519 |
| Therapeutic product effect decreased | 14.51 | 14.46 | 6 | 9845 | 277565 | 90341031 |
| Exposure during pregnancy | 14.47 | 14.46 | 4 | 9847 | 238406 | 90380190 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Lymphopenia | 39.07 | 19.26 | 23 | 3277 | 21540 | 42596495 |
| Dizziness | 22.10 | 19.26 | 55 | 3245 | 249199 | 42368836 |
| Activated partial thromboplastin time prolonged | 21.29 | 19.26 | 14 | 3286 | 15889 | 42602146 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Gastrooesophageal reflux disease | 58.18 | 14.45 | 76 | 9824 | 179900 | 110399499 |
| Pneumonia aspiration | 48.06 | 14.45 | 47 | 9853 | 81186 | 110498213 |
| Myocardial infarction | 45.61 | 14.45 | 70 | 9830 | 192013 | 110387386 |
| Coma | 36.87 | 14.45 | 49 | 9851 | 117820 | 110461579 |
| Hyponatraemia | 36.60 | 14.45 | 68 | 9832 | 217585 | 110361814 |
| Underdose | 36.15 | 14.45 | 36 | 9864 | 63518 | 110515881 |
| Crystal nephropathy | 35.29 | 14.45 | 11 | 9889 | 1845 | 110577554 |
| Completed suicide | 34.99 | 14.45 | 71 | 9829 | 242310 | 110337089 |
| Coronary artery disease | 34.28 | 14.45 | 37 | 9863 | 71653 | 110507746 |
| Blood potassium decreased | 31.42 | 14.45 | 31 | 9869 | 54083 | 110525316 |
| Diabetic neuropathy | 30.13 | 14.45 | 14 | 9886 | 6985 | 110572414 |
| Focal segmental glomerulosclerosis | 30.09 | 14.45 | 12 | 9888 | 4133 | 110575266 |
| Somnolence | 25.36 | 14.45 | 71 | 9829 | 297378 | 110282021 |
| Feeling abnormal | 21.53 | 14.45 | 49 | 9851 | 180662 | 110398737 |
| Cardiac failure congestive | 21.49 | 14.45 | 44 | 9856 | 150956 | 110428443 |
| Emotional distress | 21.18 | 14.45 | 23 | 9877 | 44824 | 110534575 |
| Tubulointerstitial nephritis | 20.83 | 14.45 | 25 | 9875 | 54259 | 110525140 |
| Ileus paralytic | 20.76 | 14.45 | 13 | 9887 | 11724 | 110567675 |
| Deep vein thrombosis | 20.19 | 14.45 | 41 | 9859 | 139846 | 110439553 |
| Pulmonary embolism | 19.06 | 14.45 | 52 | 9848 | 214422 | 110364977 |
| Fear | 18.76 | 14.45 | 16 | 9884 | 23177 | 110556222 |
| Off label use | 18.25 | 14.45 | 71 | 9829 | 1500114 | 109079285 |
| Cerebrovascular accident | 18.20 | 14.45 | 46 | 9854 | 181238 | 110398161 |
| Renal failure | 17.29 | 14.45 | 52 | 9848 | 226522 | 110352877 |
| Pyrexia | 16.40 | 14.45 | 35 | 9865 | 898230 | 109681169 |
| Infusion related reaction | 16.07 | 14.45 | 7 | 9893 | 381155 | 110198244 |
| Dry skin | 16.07 | 14.45 | 32 | 9868 | 107621 | 110471778 |
| Dizziness | 15.96 | 14.45 | 112 | 9788 | 698081 | 109881318 |
| Transient acantholytic dermatosis | 15.68 | 14.45 | 4 | 9896 | 325 | 110579074 |
| Lichenification | 15.16 | 14.45 | 5 | 9895 | 1004 | 110578395 |
| Unevaluable event | 14.62 | 14.45 | 22 | 9878 | 59205 | 110520194 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C03DB02 | CARDIOVASCULAR SYSTEM DIURETICS ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS Other potassium-sparing agents |
| FDA PE | N0000008859 | Decreased Renal K+ Excretion |
| FDA PE | N0000175359 | Increased Diuresis |
| FDA EPC | N0000175418 | Potassium-sparing Diuretic |
| MeSH PA | D004232 | Diuretics |
| MeSH PA | D026941 | Sodium Channel Blockers |
| MeSH PA | D045283 | Natriuretic Agents |
| MeSH PA | D049990 | Membrane Transport Modulators |
| MeSH PA | D062686 | Epithelial Sodium Channel Blockers |
| CHEBI has role | CHEBI:35498 | diuretic |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:38633 | sodium channel blocker |
| CHEBI has role | CHEBI:62868 | hepatoprotective agent |
| CHEBI has role | CHEBI:145947 | antiatherosclerotic agent |
Related Drugs by ATC class:
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypertensive disorder | indication | 38341003 | DOID:10763 |
| Edema | indication | 267038008 | |
| Peripheral Edema due to Chronic Heart Failure | indication | ||
| Pulmonary Edema due to Chronic Heart Failure | indication | ||
| Hypokalemia | off-label use | 43339004 | |
| Anuria | contraindication | 2472002 | DOID:2983 |
| Hypercholesterolemia | contraindication | 13644009 | |
| Hyperkalemia | contraindication | 14140009 | |
| Secondary angle-closure glaucoma | contraindication | 21571006 | |
| Hypovolemia | contraindication | 28560003 | |
| Dehydration | contraindication | 34095006 | |
| Hyperuricemia | contraindication | 35885006 | DOID:1920 |
| Diabetes mellitus type 2 | contraindication | 44054006 | DOID:9352 |
| Diabetes mellitus type 1 | contraindication | 46635009 | DOID:9744 |
| Acidosis | contraindication | 51387008 | |
| Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
| Sympathectomy | contraindication | 57071006 | |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Hyperparathyroidism | contraindication | 66999008 | DOID:13543 |
| Hypochloremic alkalosis | contraindication | 70134007 | |
| Hepatic coma | contraindication | 72836002 | DOID:12550 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Megaloblastic anemia due to folate deficiency | contraindication | 85649008 | DOID:14026 |
| Hyponatremia | contraindication | 89627008 | |
| Gout | contraindication | 90560007 | DOID:13189 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Kidney stone | contraindication | 95570007 | |
| Hypomagnesemia | contraindication | 190855004 | |
| Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Neonatal hyperbilirubinemia | contraindication | 281610001 | |
| Pregnancy, function | contraindication | 289908002 | |
| Azotemia | contraindication | 445009001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.22 | Basic |
| pKa2 | 5.5 | Basic |
| pKa3 | 2.21 | Basic |
| pKa4 | 0.54 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Amiloride-sensitive sodium channel, ENaC | Ion channel | BLOCKER | IC50 | 5.30 | IUPHAR | CHEMBL | |||
| Solute carrier family 12 member 1 | Transporter | WOMBAT-PK | |||||||
| Cytochrome P450 2D6 | Enzyme | IC50 | 5 | DRUG MATRIX | |||||
| Caspase-1 | Enzyme | IC50 | 5.44 | DRUG MATRIX | |||||
| Cathepsin G | Enzyme | IC50 | 5.13 | DRUG MATRIX | |||||
| Pteridine reductase 1 | Enzyme | Ki | 5.47 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017902 | VUID |
| N0000146253 | NUI |
| D00386 | KEGG_DRUG |
| 4017902 | VANDF |
| C0040869 | UMLSCUI |
| CHEBI:9671 | CHEBI |
| DX2 | PDB_CHEM_ID |
| CHEMBL585 | ChEMBL_ID |
| DB00384 | DRUGBANK_ID |
| D014223 | MESH_DESCRIPTOR_UI |
| 5546 | PUBCHEM_CID |
| 4329 | IUPHAR_LIGAND_ID |
| 1266 | INN_ID |
| WS821Z52LQ | UNII |
| 10763 | RXNORM |
| 5617 | MMSL |
| 80875 | MMSL |
| d00396 | MMSL |
| 002315 | NDDF |
| 12512008 | SNOMEDCT_US |
| 387053007 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0527-1632 | CAPSULE | 37.50 mg | ORAL | ANDA | 20 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0591-0348 | TABLET | 75 mg | ORAL | ANDA | 19 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0591-0424 | TABLET | 37.50 mg | ORAL | ANDA | 19 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-2074 | CAPSULE | 37.50 mg | ORAL | ANDA | 23 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10135-581 | CAPSULE | 37.50 mg | ORAL | ANDA | 20 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-049 | TABLET | 37.50 mg | ORAL | ANDA | 19 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-076 | TABLET | 37.50 mg | ORAL | NDA | 22 sections |
| Triamterene hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-080 | TABLET | 75 mg | ORAL | ANDA | 23 sections |
| Triamterene hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-536 | TABLET | 37.50 mg | ORAL | ANDA | 23 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-537 | TABLET | 75 mg | ORAL | ANDA | 19 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16590-338 | TABLET | 37.50 mg | ORAL | ANDA | 19 sections |
| Triamterene hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-496 | TABLET | 37.50 mg | ORAL | ANDA | 21 sections |
| Triamterene hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-497 | TABLET | 75 mg | ORAL | ANDA | 21 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-839 | CAPSULE | 37.50 mg | ORAL | ANDA | 23 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 33261-365 | TABLET | 75 mg | ORAL | ANDA | 19 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 33261-952 | TABLET | 37.50 mg | ORAL | ANDA | 19 sections |
| Triamterene and Hydrochlorothiazide | Human Prescription Drug Label | 2 | 33342-467 | CAPSULE | 37.50 mg | ORAL | ANDA | 11 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45865-402 | CAPSULE | 37.50 mg | ORAL | ANDA | 24 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-1270 | TABLET | 37.50 mg | ORAL | ANDA | 19 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-1834 | TABLET | 75 mg | ORAL | ANDA | 19 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-2028 | CAPSULE | 37.50 mg | ORAL | ANDA | 20 sections |
| triamterene and hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-5801 | TABLET | 37.50 mg | ORAL | ANDA | 17 sections |
| triamterene and hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-6736 | TABLET | 75 mg | ORAL | ANDA | 17 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-6944 | CAPSULE | 37.50 mg | ORAL | ANDA | 22 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-7437 | CAPSULE | 37.50 mg | ORAL | ANDA | 18 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-7438 | CAPSULE | 37.50 mg | ORAL | ANDA | 18 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51407-286 | TABLET | 37.50 mg | ORAL | ANDA | 19 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51655-217 | TABLET | 37.50 mg | ORAL | ANDA | 19 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51655-582 | TABLET | 75 mg | ORAL | ANDA | 19 sections |
| Triamterene and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51655-630 | TABLET | 37.50 mg | ORAL | ANDA | 19 sections |